Most Read Articles
Elvira Manzano, 10 Jun 2020
Intranasal esketamine reduces depression symptoms in severely ill patients with major depressive disorder (MDD) and active suicidal ideation with intent, the double-blind randomized ASPIRE 1 study has shown.
Pearl Toh, 16 Jun 2020
Adding belimumab to standard maintenance therapy significantly improves renal response in patients with active lupus nephritis compared with standard therapy alone, according to the BLISS-LN study presented at the ERA-EDTA 2020 Meeting.
Audrey Abella, 15 Jul 2020
The type I interferon receptor antibody anifrolumab reduced disease activity and flares in patients with moderate-to-severe active systemic lupus erythematosus (SLE), results of the TULIP-1 and TULIP-2 trials have shown.
Pearl Toh, 10 Jul 2019
Esketamine nasal spray effectively and rapidly improves depressive symptoms in patients with treatment-resistant depression, making it the first antidepressant to be approved by the US FDA in a new drug class.

Product Highlight - Toujeo

24 Jul 2020

Confidence in Every Step1-6
The only 450-unit Insulin Glargine in the market7

  • Treatment of type 2 diabetes mellitus in adults to lower blood sugar steadily
    over a long period of time.7
  • Highly effective in lowering HbA1c for a broad range of patient types8-11
  • Proven safe with lesser risk of hypoglycemia vs. U100 and other 2nd gen
    basal insulins8-11
  • Flatter profile and less within-day fluctuations vs. other 2nd gen basal insulins12


REFERENCES:
(1) Rosenstock J, et al. Diabetes Care. 2018 Oct 1;41/(10):2147-54.
(2) Riddle MC et al. Diabetes Care 2014 Oct.37(10)2755-62.
(3) Yki-Jarvinen H et al Diabetes Care 2014 Dec 37(12)3235-74.
(4) Boli GB et al Diabetes Obes Metab 2015 Apr. 17(4)386-94.
(5) Terauchi Y at al Diabetes Obes Metab 2016 Apr 18(4) 366-74.
(6) Home PD et al Diabetes Care 2015 Dec 38(12)2217-25 7. Matsuhisa M et al. Diabetes Obes Metab 2016 Apr 18(4) 375-83
(7) Toujeo Prescribing Info 2016.
(8) Haluzik M. et.al Presented at 79th ADA 2019, June 7-11, SA, CA, US 146-OR.
(9) Escalada FJ, et.al Diabetes Obes Metab, 2018;20:2860-2868.
(10) Sullivan SD, et al. Presented at 79th ADA 2019, June 7-11, SA, CA, US 133-LB.
(11) Charbonnel et al. Presented at 79th ADA 2019, June 7-11, SA, CA, US 133-LB.
(12) Bailey et al. DOM Accepted.



Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Philippines digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 10 Jun 2020
Intranasal esketamine reduces depression symptoms in severely ill patients with major depressive disorder (MDD) and active suicidal ideation with intent, the double-blind randomized ASPIRE 1 study has shown.
Pearl Toh, 16 Jun 2020
Adding belimumab to standard maintenance therapy significantly improves renal response in patients with active lupus nephritis compared with standard therapy alone, according to the BLISS-LN study presented at the ERA-EDTA 2020 Meeting.
Audrey Abella, 15 Jul 2020
The type I interferon receptor antibody anifrolumab reduced disease activity and flares in patients with moderate-to-severe active systemic lupus erythematosus (SLE), results of the TULIP-1 and TULIP-2 trials have shown.
Pearl Toh, 10 Jul 2019
Esketamine nasal spray effectively and rapidly improves depressive symptoms in patients with treatment-resistant depression, making it the first antidepressant to be approved by the US FDA in a new drug class.